Breaking News Instant updates and real-time market news.

TTNP

Titan Pharmaceuticals

$0.21

0.0005 (0.24%)

, MRK

Merck

$71.62

0.69 (0.97%)

07:03
10/02/18
10/02
07:03
10/02/18
07:03

Titan Pharmaceuticals appoints Dane Hallberg as Chief Commercial Officer

Titan Pharmaceuticals (TTNP) announced the appointment of Dane D. Hallberg to the newly created position of Executive Vice President and Chief Commercial Officer, effective immediately. Hallberg will be responsible for leading all of the company's commercial activities. Hallberg has a strong track record of success in the global pharmaceutical and biotech industries, building out commercial capabilities, leading marketing and sales teams, and cultivating strong thought leader relationships across multiple specialties. His 22 years of healthcare experience includes commercial leadership roles with Able Star, Sunovion Pharmaceutical, Merck (MRK), Global Healthcare Japan, Dendrite Japan and Tierra Incorporated. Most recently, he was retained by Bristol-Myers Squibb (BMY) as a consultant to provide strategic guidance and project management for its global research and development, business intelligence and analytics, and health economics and outcomes research programs.

TTNP

Titan Pharmaceuticals

$0.21

0.0005 (0.24%)

MRK

Merck

$71.62

0.69 (0.97%)

BMY

Bristol-Myers

$62.09

0.02 (0.03%)

  • 03

    Oct

  • 03

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TTNP Titan Pharmaceuticals
$0.21

0.0005 (0.24%)

11/10/17
ROTH
11/10/17
DOWNGRADE
Target $2
ROTH
Neutral
Titan downgraded to Neutral with $2 target at Roth Capital
Roth Capital analyst Scott Henry downgraded Titan Pharmaceuticals to Neutral from Buy and cut his price target for the shares to $2 from $6. Probuphine continues to miss estimates and visibility into a positive inflection point remains lacking, Henry tells investors in a research note following Titan's Q3 results.
11/10/17
ROTH
11/10/17
DOWNGRADE
ROTH
Neutral
Titan Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
MRK Merck
$71.62

0.69 (0.97%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
BMY Bristol-Myers
$62.09

0.02 (0.03%)

09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$81.15

-0.83 (-1.01%)

20:43
10/22/18
10/22
20:43
10/22/18
20:43
Initiation
Exxon Mobil initiated  »

Exxon Mobil assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$54.96

0.07 (0.13%)

, MCD

McDonald's

$166.53

-0.92 (-0.55%)

20:25
10/22/18
10/22
20:25
10/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VZ

Verizon

$54.96

0.07 (0.13%)

MCD

McDonald's

$166.53

-0.92 (-0.55%)

MM

Millennial Media

$0.00

(0.00%)

UTX

United Technologies

$126.42

-2.22 (-1.73%)

LMT

Lockheed Martin

$326.45

-1.77 (-0.54%)

NEE

NextEra Energy

$172.71

-0.76 (-0.44%)

CAT

Caterpillar

$128.64

-2.73 (-2.08%)

BIIB

Biogen

$315.67

-4.18 (-1.31%)

CNC

Centene

$141.34

-1.565 (-1.10%)

GLW

Corning

$30.83

0.06 (0.19%)

PCAR

Paccar

$60.51

0.25 (0.41%)

RF

Regions Financial

$16.39

-0.5 (-2.96%)

FITB

Fifth Third

$25.38

-0.95 (-3.61%)

HBAN

Huntington Bancshares

$13.66

-0.54 (-3.80%)

TRU

TransUnion

$68.59

0.39 (0.57%)

XRX

Xerox

$26.39

-0.47 (-1.75%)

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

JBLU

JetBlue

$16.57

0.04 (0.24%)

GPK

Graphic Packaging

$12.31

-0.4 (-3.15%)

SLCA

U.S. Silica

$15.65

-0.41 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

  • 13

    Dec

  • 14

    Dec

TOT

Total

$59.85

-0.95 (-1.56%)

20:22
10/22/18
10/22
20:22
10/22/18
20:22
Initiation
Total initiated  »

Total assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$64.88

-0.66 (-1.01%)

20:17
10/22/18
10/22
20:17
10/22/18
20:17
Initiation
Royal Dutch Shell initiated  »

Royal Dutch Shell assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$26.39

-0.6 (-2.22%)

20:13
10/22/18
10/22
20:13
10/22/18
20:13
Initiation
Equinor initiated  »

Equinor assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.23

-0.82 (-0.69%)

20:11
10/22/18
10/22
20:11
10/22/18
20:11
Initiation
Chevron initiated  »

Chevron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

COP

ConocoPhillips

$72.06

-0.43 (-0.59%)

20:06
10/22/18
10/22
20:06
10/22/18
20:06
Initiation
ConocoPhillips initiated  »

ConocoPhillips assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BP

BP

$43.15

-0.84 (-1.91%)

20:02
10/22/18
10/22
20:02
10/22/18
20:02
Initiation
BP initiated  »

BP assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:51
10/22/18
10/22
19:51
10/22/18
19:51
Upgrade
Washington REIT, Apple, Amazon.com rating change  »

Washington REIT upgraded…

WRE

Washington REIT

$27.97

-0.305 (-1.08%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

, AAPL

Apple

$220.62

1.34 (0.61%)

19:47
10/22/18
10/22
19:47
10/22/18
19:47
Upgrade
JBG Smith Properties, Apple, Amazon.com rating change  »

JBG Smith Properties…

JBGS

JBG Smith Properties

$36.81

0.005 (0.01%)

AAPL

Apple

$220.62

1.34 (0.61%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:38
10/22/18
10/22
19:38
10/22/18
19:38
Periodicals
Arconic Board evaluating $11B Apollo Global offer, Reuters reports »

Arconic is said to have…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

BX

Blackstone

$34.38

-0.28 (-0.81%)

CG

Carlyle Group

$20.46

0.29 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:34
10/22/18
10/22
19:34
10/22/18
19:34
Periodicals
Breaking Periodicals news story on Arconic, Apollo Global »

Arconic to consider $11B…

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

ENLK

EnLink Midstream Partners

$18.10

-0.19 (-1.04%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Upgrade
EnLink Midstream Partners rating change  »

EnLink Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:25
10/22/18
10/22
19:25
10/22/18
19:25
Hot Stocks
Helix Energy reports Q3 adjusted EBITDA $58.6M vs. $30.5M last year »

CEO Owen Kratz says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

HLX

Helix Energy

$10.28

0.03 (0.29%)

19:24
10/22/18
10/22
19:24
10/22/18
19:24
Earnings
Helix Energy reports Q3 adjusted EPS 18c, consensus 11c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Nov

  • 15

    Nov

UAL

United Continental

$88.62

1.19 (1.36%)

19:13
10/22/18
10/22
19:13
10/22/18
19:13
Periodicals
United CEO upbeat in memo to workers on Q3, SVBJ reports »

In an internal memo to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$34.98

0.385 (1.11%)

, EUTLF

Eutelsat Communications

$0.00

(0.00%)

19:11
10/22/18
10/22
19:11
10/22/18
19:11
Hot Stocks
Intelsat, SES, Eutelsat in transition on planning to support 5G deployment »

The C-Band Alliance,…

I

Intelsat

$34.98

0.385 (1.11%)

EUTLF

Eutelsat Communications

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CDNS

Cadence Design

$40.62

0.49 (1.22%)

, SSNC

SS&C

$49.91

-0.37 (-0.74%)

19:05
10/22/18
10/22
19:05
10/22/18
19:05
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CDNS

Cadence Design

$40.62

0.49 (1.22%)

SSNC

SS&C

$49.91

-0.37 (-0.74%)

FRBA

First Bank

$12.42

0.015 (0.12%)

ZION

Zions Bancorp

$45.33

-1.64 (-3.49%)

RNST

Renasant

$35.44

-1.1 (-3.01%)

CR

Crane

$87.33

-0.28 (-0.32%)

BRO

Brown & Brown

$29.12

0.27 (0.94%)

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

RH

RH

$109.10

-13.485 (-11.00%)

MC

Moelis

$50.66

-0.21 (-0.41%)

AMTD

TD Ameritrade

$49.89

-0.6 (-1.19%)

AFMD

Affimed N.V.

$3.15

-0.06 (-1.87%)

PTI

Proteostasis

$7.17

-0.77 (-9.70%)

EIGR

Eiger BioPharmaceuticals

$10.65

-1.2 (-10.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 31

    Oct

  • 02

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Mar

  • 23

    Oct

  • 24

    Oct

DIS

Disney

$118.22

-0.59 (-0.50%)

18:55
10/22/18
10/22
18:55
10/22/18
18:55
Periodicals
Disney spends $20M to support Florida's Amendment 3, Bloomberg says »

Disney and the Seminole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

HSBC

HSBC

$40.36

-0.095 (-0.23%)

18:50
10/22/18
10/22
18:50
10/22/18
18:50
Periodicals
HSBC teams up with Avant to offer personal loans, Bloomberg says »

HSBC Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSFS

WSFS Financial

$43.08

-0.46 (-1.06%)

18:49
10/22/18
10/22
18:49
10/22/18
18:49
Earnings
WSFS Financial reports Q3 EPS 96c, consensus 92c »

Reports Q3 NII $63.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IQV

Iqvia

$126.36

-0.52 (-0.41%)

, CRM

Salesforce

$142.92

2.47 (1.76%)

18:22
10/22/18
10/22
18:22
10/22/18
18:22
Recommendations
Iqvia, Salesforce analyst commentary at Piper Jaffray »

Iqvia price target raised…

IQV

Iqvia

$126.36

-0.52 (-0.41%)

CRM

Salesforce

$142.92

2.47 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

  • 03

    Mar

BK

BNY Mellon

$46.47

-0.94 (-1.98%)

18:20
10/22/18
10/22
18:20
10/22/18
18:20
Hot Stocks
BNY Mellon, Bank of the West reach pact on new real-time payments solution »

BNY Mellon and Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLGX

CoreLogic

$45.36

-0.01 (-0.02%)

18:07
10/22/18
10/22
18:07
10/22/18
18:07
Hot Stocks
CoreLogic to acquire Symbility Solutions for CAD159.5M »

Symbility Solutions and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ABBV

AbbVie

$84.27

-3.74 (-4.25%)

18:04
10/22/18
10/22
18:04
10/22/18
18:04
Hot Stocks
AbbVie reports 'positive' data from Phase 2b/3 study of upadacitinib »

AbbVie announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.